Fourth independent MCO confirmation of 2026 Medicaid trough. MOH at $131 (RSI 17, -54% 1Y) trades at 8x management's $5 trough EPS guide. The operating leverage is enormous: 100bps MCR improvement on $32B Medicaid base = ≈$5/share. Embedded earnings from signed contracts exceed $11/share. But there's a covenant amendment filed the same day as the earnings call that changes the risk profile materially.

The Setup

Cross-ticker convergence. Four major Medicaid MCOs independently calling 2026 as trough:

  • MOH (this filing): "300-400bps underfunded" per regulatory filings, rates using 2024 baseline while 2025 saw 7.5% medical cost trend
  • ELV: "Trough year for Medicaid," -1.75% margin, mid-single-digit trend vs mid-single-digit rates (lagging)
  • CNC: Sequential HBR improvement (94.9% → 93.4% → 93.0%), identified ABA behavioral health as ≈50% of excess trend with specific cost lever
  • INNV (PACE provider): 8% Medicaid rate increases in Q2 FY2026, operational turnaround ($13.3M op income vs $12.6M loss YoY)

The actuarial self-correction mechanism is known and documented. State Medicaid rates are set using prior-year cost baselines with 12-18 month lag. When medical cost trend accelerates unexpectedly (4.5% expected → 7.5% actual in 2025), rates lag by construction. Management got 150bps mid-cycle adjustment in 2025. Full actuarial catch-up happens through the standard rate-setting process.

Redetermination acuity shift winding down. The 250bps acuity impact from 2024-2025 redeterminations (low/no-utilizers exiting) is done. 2026 attrition expected at 2% vs 13% in 2024. The worst of the mix shift is behind.

Operating Leverage at $131

Management's math:

  • Trough 2026 guide: ≈$5 EPS ($42B premium, 0.8% pretax margin)
  • Underlying business: ≈$7.50 EPS ex $1.50 Florida CMS ramp drag, $1 MAPD exit headwind
  • Embedded earnings: $11+ from signed contracts not yet at run rate (Florida CMS $6B annual premium late 2026 go-live, Georgia + Texas STAR CHIP 2027)
  • Operating leverage: 100bps MCR improvement = ≈$5/share on $32B Medicaid revenue base

If Medicaid margins normalize even halfway (150-200bps improvement from actuarial catch-up), you're looking at $12-15 earnings power on a $131 stock. At a normal MCO multiple of 12-15x, that's $144-225 vs $131 today.

Growth levers: 90% RFP win rate, $50B active pipeline, M&A at book value (vs historical 20%+ premiums) as smaller single-state MCOs erode capital in same rate environment.

The Kill Risk: Covenant Amendment

Feb 4, 2026 covenant amendment (8-K filed Feb 6, same day as earnings call):

  • Interest coverage ratio slashed from 3.0x to 1.75x for all of 2026 (42% relief)
  • Step-up schedule: 2.0x (Q1 2027), 2.5x (Q2), 2.75x (Q3), back to 3.0x (Q4 2027)
  • Combined with negative $535M FY2025 operating cash flow
  • $1B term loans maturing Feb/Aug 2027 ($500M + $500M delayed draw per 10-Q)
  • $93M non-cash impairment from MAPD exit
  • 3.7x debt/EBITDA, debt-to-cap 49%

Revolver undrawn ($1.25B available) and regulated subs paid $648M dividends to parent through Q3 2025, so liquidity exists. But the covenant amendment four days after quarter-end signals either near-breach or proactive distress management.

This is not just a valuation trade. It's a solvency gate. If Medicaid margins don't recover by mid-2027 (when term loans mature), the 1.75x covenant could bind and create a refinancing risk at elevated rates. The -$535M operating cash flow in FY2025 means they're burning cash while waiting for the actuarial cycle to turn.

What Changes the Thesis

Bull case accelerants:

  • Mid-cycle rate adjustments in 2026 (precedent: got 150bps in 2025)
  • Medical cost trend moderates faster than expected (redetermination acuity shift done, ABA behavioral health lever per CNC)
  • Florida CMS ramp delivers ahead of late-2026 schedule
  • Refinancing term loans before maturity at manageable rates

Bear case (thesis breaks):

  • Medical cost trend is structural reset (7.5% is new normal, not cyclical peak)
  • Covenant breach before margins recover → distressed refinancing or dilutive equity raise
  • OB3 Medicaid cuts (work requirements, semiannual redeterminations 2027+) hit harder than 2-4% membership decline estimate
  • ACA subsidy expiration craters Marketplace (deliberately reduced to $2.2B from $4.5B, but still a headwind)

Epistemic State: Doorway

60% mean-reversion, 40% structural margin reset. Three independent MCOs calling trough + known actuarial mechanism + winding-down acuity shift = reversion thesis has legs. But the covenant amendment is new information that adds a timing constraint. You need margins to recover before mid-2027 maturities, not just "eventually."

Catalyst timeline:

  • Q1 2026 earnings (late April): First read on whether 2026 is tracking to trough guide or deteriorating further
  • Mid-cycle rate adjustments (2026): Precedent exists (150bps in 2025), would accelerate recovery
  • Feb/Aug 2027: Term loan maturities create hard deadline for margin recovery or refinancing

Gaps Before Sizing

Critical unknowns:

  1. Covenant compliance trajectory — What's the actual interest coverage ratio Q4 2025? How much buffer to 1.75x floor?
  2. Term loan refinancing options — Can they refi the $1B before maturity at acceptable rates given current credit profile?
  3. Florida CMS ramp timeline precision — Late 2026 go-live, but when does it actually contribute to earnings? Q4 2026 or 2027?
  4. Cross-ticker validation — CNC and ELV also calling trough, but do they have similar covenant/liquidity stress or is MOH uniquely constrained?

What This Is

Covenant-constrained mean-reversion with documented cross-ticker convergence. The actuarial self-correction mechanism is real (four MCOs confirm), the operating leverage is real ($5/share per 100bps), the embedded earnings are real ($11+ from signed contracts).

But you don't size with 1.75x interest coverage, negative cash flow, and $1B maturities in 15 months until the solvency gate clears. Needs covenant/liquidity deep dive first.